Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
:NBY
Total Valuation
NovaBay Pharma has a market cap or net worth of $3.40M. The enterprise value is $4.18M.
Market Cap$3.40M
Enterprise Value$4.18M
Share Statistics
NovaBay Pharma has 5,816,204 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,816,204
Owned by Insiders17.20%
Owned by Institutions1.35%
Financial Efficiency
NovaBay Pharma’s return on equity (ROE) is 66.73 and return on invested capital (ROIC) is -559.83%.
Return on Equity (ROE)66.73
Return on Assets (ROA)-2.51
Return on Invested Capital (ROIC)-559.83%
Return on Capital Employed (ROCE)-10.07
Revenue Per Employee749.77K
Profits Per Employee-555.62K
Employee Count13
Asset Turnover2.85
Inventory Turnover4.27
Valuation Ratios
The current PE Ratio of NovaBay Pharma is -0.24. NovaBay Pharma’s PEG ratio is <0.01.
PE Ratio-0.24
PS Ratio0.28
PB Ratio-15.82
Price to Fair Value-15.82
Price to FCF-0.39
Price to Operating Cash Flow-0.39
PEG Ratio<0.01
Income Statement
In the last 12 months, NovaBay Pharma had revenue of 9.75M and earned -8.61M in profits. Earnings per share was -2.53.
Revenue9.75M
Gross Profit6.48M
Operating Income-5.84M
Pretax Income-8.61M
Net Income-8.61M
EBITDA-5.92M
Earnings Per Share (EPS)-2.53
Cash Flow
In the last 12 months, operating cash flow was -5.18M and capital expenditures -6.00K, giving a free cash flow of -5.19M billion.
Operating Cash Flow-5.18M
Free Cash Flow-5.19M
Free Cash Flow per Share-0.89
Dividends & Yields
NovaBay Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change-78.52%
50-Day Moving Average0.60
200-Day Moving Average0.72
Relative Strength Index (RSI)50.73
Average Volume (3m)56.82K
Important Dates
NovaBay Pharma upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateApr 5, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
NovaBay Pharma as a current ratio of 0.68, with Debt / Equity ratio of -1296.12%
Current Ratio0.68
Quick Ratio0.41
Debt to Market Cap0.57
Net Debt to EBITDA-0.13
Interest Coverage Ratio-6.46
Taxes
In the past 12 months, NovaBay Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NovaBay Pharma EV to EBITDA ratio is -0.47, with an EV/FCF ratio of -0.54.
EV to Sales0.29
EV to EBITDA-0.47
EV to Free Cash Flow-0.54
EV to Operating Cash Flow-0.54
Balance Sheet
NovaBay Pharma has $430.00K in cash and marketable securities with $1.67M in debt, giving a net cash position of $1.24M billion.
Cash & Marketable Securities$430.00K
Total Debt$1.67M
Net Cash$1.24M
Net Cash Per Share$0.21
Tangible Book Value Per Share-$0.04
Margins
Gross margin is 66.26%, with operating margin of -59.91%, and net profit margin of -88.31%.
Gross Margin66.26%
Operating Margin-59.91%
Pretax Margin-88.31%
Net Profit Margin-88.31%
EBITDA Margin-60.79%
EBIT Margin-64.70%
Analyst Forecast
The average price target for NovaBay Pharma is $0.85, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.85
Price Target Upside46.55% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast-33.58%
EPS Growth Forecast93.83%